ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has ViewRay's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VRAY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: VRAY's weekly volatility has decreased from 14% to 8% over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: VRAY exceeded the US Medical Equipment industry which returned 31% over the past year.
Return vs Market: VRAY exceeded the US Market which returned 39.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ViewRay's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StViewRay (NASDAQ:VRAY) Shareholders Booked A 57% Gain In The Last Year
4 months ago | Simply Wall StRead This Before Selling ViewRay, Inc. (NASDAQ:VRAY) Shares
5 months ago | Simply Wall StHow Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?
Is ViewRay undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VRAY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VRAY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VRAY is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: VRAY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VRAY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VRAY is overvalued based on its PB Ratio (6.4x) compared to the US Medical Equipment industry average (4.5x).
How is ViewRay forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VRAY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VRAY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VRAY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VRAY's revenue (25.5% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: VRAY's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VRAY is forecast to be unprofitable in 3 years.
How has ViewRay performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VRAY is currently unprofitable.
Growing Profit Margin: VRAY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VRAY is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare VRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VRAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (20%).
Return on Equity
High ROE: VRAY has a negative Return on Equity (-65.16%), as it is currently unprofitable.
How is ViewRay's financial position?
Financial Position Analysis
Short Term Liabilities: VRAY's short term assets ($252.6M) exceed its short term liabilities ($49.2M).
Long Term Liabilities: VRAY's short term assets ($252.6M) exceed its long term liabilities ($74.3M).
Debt to Equity History and Analysis
Debt Level: VRAY's debt to equity ratio (34.7%) is considered satisfactory.
Reducing Debt: VRAY had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VRAY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VRAY has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 16.7% each year.
What is ViewRay current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VRAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VRAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VRAY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VRAY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VRAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Drake (53 yo)
Mr. Scott William Drake has been the President, Chief Executive Officer and Director of ViewRay, Inc., since July 24, 2018. Mr. Drake served as Director of AtriCure Inc. since September 2013 until May 2021...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD7.14M) is above average for companies of similar size in the US market ($USD2.44M).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
Experienced Management: VRAY's management team is considered experienced (2.8 years average tenure).
Experienced Board: VRAY's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.7%.
ViewRay, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: ViewRay, Inc.
- Ticker: VRAY
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.045b
- Shares outstanding: 161.74m
- Website: https://www.viewray.com
Number of Employees
- ViewRay, Inc.
- 2 Thermo Fisher Way
- United States
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MR...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/24 23:11|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.